Road to the Clinic for Small Molecules

Road to the Clinic for Small Molecules

Whether your goal is to develop a pipeline through commercial launch or partner as early as possible, submitting a Clinical Trial Application (CTA) is a critical early milestone for every biotech company. With large healthcare companies and Venture Capital firms competing for the most promising compounds, startups are expected to demonstrate a clear blueprint for CTA approval, and we want you to be ready.

Johnson & Johnson Innovation – JLABS (JLABS) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) invite you to an in-depth look into different aspects in the journey towards filing a CTA for small molecules including also Antisense Oligonucleotides (ASOs), siRNA and small peptides. This program targets early innovators and first-time entrepreneurs, but we also welcome stakeholders supporting these startups.

Join us for a series of short presentations exploring the basic requirements and considerations necessary for small molecule CTA submission. The presentations will highlight the following:
• Preclinical development strategies for pharmacokinetics, drug metabolism and toxicology
• Key chemistry, manufacturing & controls strategies to balance cost, time and quality risks
• Designing first-in-human trials to highlight the qualities of your molecule
• Regulatory strategy, CTA requirements, and pre-CTA meetings

In case you cannot join us in person in Leiden, the Netherlands, you are welcome to register to receive the recording.


  • 12:30 CEST Registration opens
  • 13:00 CEST Introduction to Johnson & Johnson Innovation
  • Tess Korthout | Early Innovation Partner, Johnson & Johnson Innovation
  • 13:15 CEST Nonclinical Safety
  •  Ann Lampo | EU Head Nonclinical Safety Leaders and Therapeutic Area Lead, Preclinical Sciences and Translational Safety, Janssen R&D 
  • 13:45 CEST Drug Metabolism Pharmacokinetics
  • Mario Monshouwer | 
  • 14:15 CEST Chemistry, Manufacturing and Controls
  • Bart Vaningelgem | Scientific Director, Janssen R&D 
  • 15:00 CEST Break
  • 15:25 CEST Clinical Pharmacology
  • Erik Mannaert | Deputy Head, Janssen Clinical Pharmacology Unit, Janssen R&D
  • 16:10 CEST Regulatory Affairs
  • Jens Heile | Director EMEA Regulatory Affairs Immunology, Janssen R&D 
  • 16:55 CEST Closing remarks
  • 17:00 CEST Extended Q&A
  • 18:00 CEST Program close


Early innovators and first-time entrepreneurs are welcome to register here They also welcome stakeholders supporting these startups.

Bron: Johnson & Johnson Innovation

‹ Events overview